United States - English - NLM (National Library of Medicine)

amneal pharmaceuticals of new york llc - doxycycline (unii: n12000u13o) (doxycycline anhydrous - unii:334895s862) - doxycycline anhydrous 150 mg - to reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline capsules, usp and other antibacterial drugs, doxycycline capsules, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. doxycycline is indicated for the treatment of the following infections: rocky mountain spotted fever, typhus fever and the typhus group, q fever, rickettsialpox, and tick fevers caused by rickettsiae . respiratory tract infections caused by mycoplasma pneumoniae . lymphogranuloma venereum caused by chlamydia trachomatis . psittacosis (ornithosis) caused by chlamydophila psittaci . trachoma caused by chlamydia trachomatis , although the infectious agent is not

United States - English - NLM (National Library of Medicine)

american health packaging - doxycycline (unii: n12000u13o) (doxycycline anhydrous - unii:334895s862) - doxycycline anhydrous 100 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets, usp and other antibacterial drugs, doxycycline tablets, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. doxycycline tablets, usp are indicated for the treatment of the following infections: rocky mountain spotted fever, typhus fever and the typhus group, q fever, rickettsialpox, and tick fevers caused by rickettsiae . respiratory tract infections caused by mycoplasma pneumoniae . lymphogranuloma venereum caused by chlamydia trachomatis . psittacosis (ornithosis) caused by chlamydophila psittaci . trachoma caused b

United States - English - NLM (National Library of Medicine)

denton pharma, inc. dba northwind pharmaceuticals - doxycycline hyclate (unii: 19xts3t51u) (doxycycline anhydrous - unii:334895s862) - doxycycline anhydrous 100 mg - to reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate capsules & doxycycline hyclate tablets and other antibacterial drugs, doxycycline hyclate capsules & doxycycline hyclate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. - doxycycline is indicated for the treatment of the following infections: rocky mountain spotted fever, typhus fever and the typhus group, q fever, rickettsialpox, and tick fevers caused by rickettsiae. respiratory tract infections caused by mycoplasma pneumoniae . lymphogranuloma venereum caused by chlamydi

United States - English - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - doxycycline (unii: n12000u13o) (doxycycline anhydrous - unii:334895s862) - to reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline capsules, usp and other antibacterial drugs, doxycycline capsules, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. doxycycline is indicated for the treatment of the following infections:     rocky mountain spotted fever, typhus fever and the typhus group, q fever, rickettsialpox, and tick fevers caused by rickettsiae.     respiratory tract infections caused by mycoplasma pneumoniae .     lymphogranuloma venereum caused by chlamydia trachomatis .     psittacosis (ornithosis) caused by chlamydophila psittaci .     trachoma caused by chlamydia trachomatis , although the i

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - doxycycline hyclate, quantity: 115.4 mg (equivalent: doxycycline, qty 100 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; maize starch; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; indigo carmine; macrogol 4000 - infections caused by the following organisms; mycoplasma pneumoniae (primary atypical pneumonia); rickettsiae (queensland tick typhus, epidemic typhus fever, q fever, murine endemic typhus fever, australo-pacific endemic scrub typhus); chlamydia psittaci (psittacosis); chlamydia trachomatis (lymphogranuloma venereum, trachoma, inclusion conjunctivitis). (doxycycline is indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. inclusion conjunctivitis may be treated with oral doxycycline alone, or in combination with topical agents). borreliae (relapsing fever). calymmatobacterium (donovania) granulomatis (granuloma inguinale). infection caused by the following gram-negative microorganisms: vibrio species (chlorea), brucella sp. (brucellosis; in conjunction with streptomycin), haemophilus ducreyi (chancroid), yersinia pestis (plague), francisella turarenis (tularaemia), bartonella bacilliformis (bartonellosis), bacteroides sp. when penicillin is contraindicated, doxy-100 is an alternative drug in the treatment of infections due to : treponema pallidum (syphilis); treponema pertenue (yaws); neisseria gonorrhoea (see dosage and administration). doxy-100 is not the drug of choice in the treatment of any type of staphylococcal infection or infections due to streptococcus pneumoniae, haemophilus influenzae, streptococcus pyogenes, streptococcus faecalis or any type of enteric bacteria because many strains of these organisms have been shown to be resistant to doxycycline. doxy-100 should not be used in these infections unless the organism has been shown to be sensitive. for upper respiratory infections due to group a beta-haemolytic streptococci (including prophylaxis of rheumatic fever), penicillin is the usual drug of choice. in acute intestinal amoebiasis, doxycycline may be a useful adjunct to amoebicides. in severe acne, doxycycline may be useful adjunctive therapy. doxycycline is indicated, in adults and children older than 10 years, as chemoprophylaxis for malaria caused by plasmodium falciparum and, in combination with other antimalarial agents, against malaria caused by plasmodium vivax. doxycycline is only able to suppress malaria caused by p. vivax. as there are relatively few locations where p. vivax does not co-exist to some extent with p. falciparum, it is recommended that doxycycline should be used routinely with other agents, for example, chloroquine.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - doxycycline hyclate, quantity: 57.7 mg (equivalent: doxycycline, qty 50 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; maize starch; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; indigo carmine; macrogol 4000 - in severe acne doxycycline may be useful adjunctive therapy. note. the 50mg tablet is not a paediatric formulation.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - doxycycline monohydrate, quantity: 52.05 mg (equivalent: doxycycline, qty 50 mg) - tablet, uncoated - excipient ingredients: colloidal anhydrous silica; sodium starch glycollate; magnesium stearate; microcrystalline cellulose; hydrogenated castor oil; povidone - infections caused by the following micro-organisms: mycoplasma pneumoniae (primary atypical pneumonia); rickettsiae (queensland tick typhus, epidemic typhus fever, q fever, murine endemic typhus fever, australo-pacific endemic scrub typhus); chlamydia psittaci (psittacosis); chlamydia trachomatis (lymphogranuloma venereum, trachoma, inclusion conjunctivitis). (doxycycline is indicated in the treatment of trachoma, although the infectious agent is not always elminated, as judged by immunofluorescence. inclusion conjunctivitis may be treated with oral doxycycline, or in combination with topical agents.) borreliae (relapsing fever); calymmatobacterium (donovania) granulomatis (granuloma inguinale). doxycycline sandoz is indicated for the treatment of anthrax due to bacillus anthracis, including inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized bacillus anthracis (see dosage and administration). infections caused by the following gram-negative micro-organisms: vibrio sp. (cholera); brucella sp. (brucellosis; in conjunction with streptomycin); yersinia pestis (plague); francisella tularensis (tularaemia); bartonella bacilliformis (bartonellosis); bacteriodes sp. when penicillin is contraindicated, doxycycline is an alternative medicine in the treatment of infections due to: treponema pallidum (syphilis); treponema pertenue (yaws); neisseria gonorrhoea (see dosage and administration). note: doxycycline sandoz is not the medicine of choice in the treatment of any type of staphylococcal infection or infections caused by streptococcus pneumoniae, haemophilus influenzae, streptococcus pyogenes, streptococcus faecalis or any type of enteric bacteria because many strains of these organisms have been shown to be resistant to doxycycline. doxycycline sandoz should not be used in these infections unless the organism has been shown to be sensitive. for upper respiratory infections due to group a beta-haemolytic streptococci (including prophylaxis of rheumatic fever), penicillin is the usual medicine of choice. in acute intestinal amoebiasis doxycycline sandoz may be a useful adjunct to amoebicides. in severe acne doxycycline may be a useful adjunctive therapy. doxycycline is indicated, in adults and children older than 10 years, as chemoprophylaxis for malaria caused by plasmodium falciparum and, in combination with other antimalarial agents, against malaria caused by plasmodium vivax. doxycycline is only able to suppress malaria caused by plasmodium vivax. as there are relatively few locations where p. vivax does not coexist to some extent with p. falciparum, it is recommended that doxycycline should be used routinely with other agents, for example chloroquine.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - doxycycline monohydrate, quantity: 104.1 mg (equivalent: doxycycline, qty 100 mg) - tablet, uncoated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; sodium starch glycollate; hydrogenated castor oil; povidone; magnesium stearate - infections caused by the following micro-organisms: mycoplasma pneumoniae (primary atypical pneumonia); rickettsiae (queensland tick typhus, epidemic typhus fever, q fever, murine endemic typhus fever, australo-pacific endemic scrub typhus); chlamydia psittaci (psittacosis); chlamydia trachomatis (lymphogranuloma venereum, trachoma, inclusion conjunctivitis). (doxycycline is indicated in the treatment of trachoma, although the infectious agent is not always elminated, as judged by immunofluorescence. inclusion conjunctivitis may be treated with oral doxycycline, or in combination with topical agents.) borreliae (relapsing fever); calymmatobacterium (donovania) granulomatis (granuloma inguinale). doxycycline sandoz is indicated for the treatment of anthrax due to bacillus anthracis, including inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized bacillus anthracis (see dosage and administration). infections caused by the following gram-negative micro-organisms: vibrio sp. (cholera); brucella sp. (brucellosis; in conjunction with streptomycin); yersinia pestis (plague); francisella tularensis (tularaemia); bartonella bacilliformis (bartonellosis); bacteriodes sp. when penicillin is contraindicated, doxycycline is an alternative medicine in the treatment of infections due to: treponema pallidum (syphilis); treponema pertenue (yaws); neisseria gonorrhoea (see dosage and administration). note: doxycycline sandoz is not the medicine of choice in the treatment of any type of staphylococcal infection or infections caused by streptococcus pneumoniae, haemophilus influenzae, streptococcus pyogenes, streptococcus faecalis or any type of enteric bacteria because many strains of these organisms have been shown to be resistant to doxycycline. doxycycline sandoz should not be used in these infections unless the organism has been shown to be sensitive. for upper respiratory infections due to group a beta-haemolytic streptococci (including prophylaxis of rheumatic fever), penicillin is the usual medicine of choice. in acute intestinal amoebiasis doxycycline sandoz may be a useful adjunct to amoebicides. in severe acne doxycycline may be a useful adjunctive therapy. doxycycline is indicated, in adults and children older than 10 years, as chemoprophylaxis for malaria caused by plasmodium falciparum and, in combination with other antimalarial agents, against malaria caused by plasmodium vivax. doxycycline is only able to suppress malaria caused by plasmodium vivax. as there are relatively few locations where p. vivax does not coexist to some extent with p. falciparum, it is recommended that doxycycline should be used routinely with other agents, for example chloroquine.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - doxycycline hyclate, quantity: 115.4 mg (equivalent: doxycycline, qty 100 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; maize starch; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; indigo carmine; macrogol 4000 - other conditions: protect from moisture. indications: infections caused by the following organisms; mycoplasma pneumoniae (primary atypical pneumonia); rickettsiae (queensland tick typhus, epidemic typhus fever, q fever, murine endemic typhus fever, australo-pacific endemic scrub typhus); chlamydia psittaci (psittacosis); chlamydia trachomatis (lymphogranuloma venereum, trachoma, inclusion conjunctivitis). (doxycycline is indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. inclusion conjunctivitis may be treated with oral doxycycline alone, or in combination with topical agents). borreliae (relapsing fever). calymmatobacterium (donovania) granulomatis (granuloma inguinale). infections caused by the following gram- negative microorganisms: vibrio species (chlorea), brucella sp. (brucellosis; in conjuction with streptomycin), haemophilus ducreyi (chancroid), yersinia pestis (plague), francisella turarenis (tularaemia), bartonella bacilliformis (bartonellosis), bacteroides sp. when penicillin is contraindicated, doxy-100 is an alternative drug in the treatment of infections due to: treponema pallidum (syphilis); treponema pertenue (yaws); neisseria gonorrhoea (see dosage and administration). doxy-100 is not the drug of choice in the treatment of any type of staphylococcal infection or infections due to streptococcus pneumoniae, haemophilus infuenzae, streptococcus pyogenes, streptococcus faecalis or any type of enteric bacteria because many strains of these organisms have been shown to be resistant to doxycycline. doxy-100 should not be used in these infections unless the organism has been shown to be sensitive. for upper respiratory infections due to group a beta-haemolytic streptococci (including prophylaxis of rheumatic fever), penicillin is the usual drug of choice. in acute intestinal amoebiasis, doxycycline may be a useful adjunct to amoebicides. in severe acne, doxycycline may be useful adjunctive therapy. doxycycline is indicated, in adults and children older than 10 years, as chemoprophylaxis for malaria caused by plasmodium falciparum and, in combination with other antimalarial agents, against malaria caused by plasmodium vivax. doxycycline is only able to suppress malaria caused by p. vivax. as there are relatively few locations where p. vivax does not co-exist to some extent with p. falciparum, it is recommended that doxycycline should be used routinely with other agents, for example, chloroquine.

United States - English - NLM (National Library of Medicine)

mylan institutional llc - doxycycline hyclate (unii: 19xts3t51u) (doxycycline anhydrous - unii:334895s862) - doxycycline anhydrous 100 mg in 10 ml - to reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline for injection and other antibacterial drugs, doxycycline for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. doxycycline is indicated in infections caused by the following microorganisms: the following gram-negative microorganisms: because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug